TNNC1

TNNC1 Full Name

troponin C type 1 (slow)

TNNC1 Introduction

A growing number of studies in cardiovascular and muscle biology highlight the difficulty of linking molecular alterations to measurable defects in contractile performance. TNNC1 (troponin C type 1) encodes the cardiac and slow skeletal muscle isoform of troponin C, a key calcium-binding protein within the troponin complex that regulates actin–myosin interactions. Predominantly expressed in cardiomyocytes and slow-twitch skeletal muscle fibers, TNNC1 plays an essential role in maintaining the precise timing and strength of muscle contraction. Its EF-hand domains enable calcium ion binding, triggering conformational changes that initiate contraction. Because this calcium-dependent mechanism is highly sensitive, even subtle structural variations in TNNC1 can disrupt normal contractile dynamics, making it a critical focus for both basic research and therapeutic development.

Functionally, TNNC1 operates as a calcium sensor that converts intracellular calcium signals into mechanical force. Upon calcium binding, TNNC1 undergoes structural rearrangement, allowing the troponin complex to relieve inhibition on actin filaments and facilitate myosin engagement. Variants in key calcium-binding regions can significantly alter calcium affinity, leading to either increased sensitivity (enhanced contractility) or reduced responsiveness (impaired contraction). Computational modeling and biochemical studies have identified mutations that may enhance calcium binding, offering a potential framework for designing calcium sensitizers in heart failure treatment. At the same time, loss-of-function variants can weaken contractile efficiency and contribute to disease progression. Beyond its canonical role, emerging evidence suggests TNNC1 may influence signaling pathways involved in cellular stress responses and proliferation, expanding its biological significance beyond muscle contraction alone.

Clinically, TNNC1 is associated with a wide spectrum of diseases that reflect its central role in muscle physiology. Pathogenic variants have been linked to cardiomyopathies, including hypertrophic and dilated forms, where disrupted calcium handling leads to abnormal cardiac function and remodeling. In developmental disorders such as Ebstein's anomaly and left ventricular hypertrabeculation, newly reported TNNC1 mutations suggest a role in early cardiac morphogenesis, possibly through altered contractile signaling during embryogenesis. Additionally, TNNC1 mutations contribute to congenital myopathies by impairing skeletal muscle mechanics, resulting in muscle weakness and reduced endurance. Notably, recent findings also identify TNNC1 as a potential tumor suppressor in lung adenocarcinoma, where decreased expression is associated with enhanced tumor growth and poor clinical outcomes. This multifaceted disease relevance underscores TNNC1 as both a promising biomarker and a challenging therapeutic target in translational medicine.

Alternate Names for TNNC1

Cardiac troponin C; CMH7; TnC; Slow troponin C1; TN C; TNC; TNNC 1; TNNC; TNNC1; TNNC1 protein

• 1.van de Locht M, et al.; Troponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics. Int J Mol Sci. 2021, 22(17):9187.
  2.Kim S, et al.; Characterization of TNNC1 as a Novel Tumor Suppressor of Lung Adenocarcinoma. Mol Cells. 2020, 43(7):619-631.